A retrospective study to evaluate clinical variables associated with overall survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with sipuleucel-T immunotherapy
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jun 2018 Safety results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 06 Jul 2017 New trial record
- 06 Jun 2017 Results (n=43) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.